The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Karpilova M.A.

FGBU "Nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ" RAMN, Moskva

Durzhinskaya M.H.

Research Institute of Eye Diseases, 11A Rossolimo St., Moscow, Russian Federation, 119021

Anti-VEGF drugs in the treatment of neovascular glaucoma

Authors:

Karpilova M.A., Durzhinskaya M.H.

More about the authors

Journal: Russian Annals of Ophthalmology. 2019;135(5‑2): 299‑304

DOI: 10.17116/oftalma2019135052299

Read: 176 times

Download PDF (RU)
Contact the author
Table of contents

ANTI-VEGF DRUGS IN THE TREATMENT OF NEOVASCULAR GLAUCOMA
ANTI-VEGF DRUGS IN THE TREATMENT OF NEOVASCULAR GLAUCOMA

To cite this article:

Karpilova MA, Durzhinskaya MH. Anti-VEGF drugs in the treatment of neovascular glaucoma. Russian Annals of Ophthalmology. 2019;135(5‑2):299‑304. (In Russ.)
https://doi.org/10.17116/oftalma2019135052299

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Effi­cacy of brolucizumab in the treatment of reti­nal pathologies: a review of post-marketing studies. Russian Annals of Ophthalmology. 2024;(5):154-161
Mana­gement of patients with treatment-resistant neovascular age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2024;(6):63-68
Choroidal neovascularization asso­ciated with choroidal nevi. Russian Annals of Ophthalmology. 2025;(1):104-112
Abstract:

Neovascular glaucoma (NVG) is the most frequently occurring type of secondary glaucoma characterized by significant decrease in visual functions. Its pathogenesis consists mainly of ischemia of the posterior segment, which is often secondary to proliferative diabetic retinopathy or ischemic central retinal vein occlusion. Development of neovascularization in the eye is associated with processes that change homeostatic balance between proangiogenic (vascular endothelial growth factor (VEGF)) and antiangiogenic (pigment epithelium-derived factor (PEDF)) factors. The aim of the therapy is to reduce the production of aqueous humour. Application of antiangiogenic preparations in patients with NVG as adjuvant therapy is the method of choice for both prevention and treatment of the disease. The article reviews literature on current possibilities of using anti-VEGF drugs in the treatment of NVG.

Keywords:

neovascular glaucoma
VEGF
PEDF
antiangiogenic therapy

Authors:

Karpilova M.A.

FGBU "Nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ" RAMN, Moskva

Durzhinskaya M.H.

Research Institute of Eye Diseases, 11A Rossolimo St., Moscow, Russian Federation, 119021

Close metadata

References:

  1. Olmos LC, Lee RK. Medical and surgical treatment of neovascular glaucoma. Int Ophthalmol Clin. 2011;51:27-36. https://doi.org/10.1097/IIO.0b013e31821e5960
  2. Sivak-Callcott JA, O’Day DM, Gass JD. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108:1767-1776.
  3. Kim YH, Sung MS, Park SW. Clinical Features of Ocular Ischemic Syndrome and Risk Factors for Neovascular Glaucoma. Korean J Ophthalmol. 2017;31(4):343-350. https://doi.org/10.3341/kjo.2016.0067
  4. Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res. 2007;26:470-485. https://doi.org/10.1016/j.preteyeres.2007.06.001
  5. Fernandez-Vigo J, Castro J, Macarro A. Diabetic iris neovascularization. Natural history and treatment. Acta Ophthalmol Scand. 1997;75(1):89-93.
  6. Chen HF, Chen MC, Chuang LH. Neovascular glaucoma after central retinal vein occlusion in pre-existing glaucoma. BMC Opthalmol. 2014;5(14):119. https://doi.org/10.1186/1471-2415-14-119
  7. Duker JS, Sivalingam AS, Brown GC, Reber R. A prospective study of acute central retinal artery obstruction. The incidence of secondary ocular neovascularization. Arch Ophthalmol. 1991;109:339-342.
  8. Hu DN, Ritch R, Liebmann J. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma. 2002;11:406-410.
  9. Rudko AS, Efendieva MH, Budzinskaya MV, Karpilova MA. Effect of vascular endothelial growth factor on angiogenesis and neurogenesis. Vestnik oftal’mologii. 2017;133(3):75-80. (In Russ.) https://doi.org/10.17116/oftalma2017133375-80
  10. Kim YG, Hong S, Lee CS. Level of vascular endothelial growth factor in aqueous humor and surgical results of ahmed glaucoma valve implantation in patients with neovascular glaucoma. J Glaucoma. 2009;18:443-447. https://doi.org/10.1097/IJG.0b013e3181895e5c
  11. Zhou M, Chen S, Wang W. Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab. Invest Ophthalmol Vis Sci. 2013;54:3874-3879. https://doi.org/10.1167/iovs.12-11507
  12. Chono I, Miyazaki D, Miyake H. High interleukin-8 level in aqueous humor is associated with poor prognosis in eyes with open angle glaucoma and neovascular glaucoma. Sci Rep. 2018;8(1):1453. https://doi.org/10.1038/s41598-018-32725-3
  13. Kuzmin AG, Lipatov DV, Chistyakov TA. Vascular endothelial growth factor in the fluid of the anterior chamber of the eye in patients with diabetic retinopathy, cataracts and neovascular glaucoma. Saharnyj diabet. 2010;(3):32-36. (In Russ.)
  14. Sakalova ED, Avetisov KS, Budzinskaya MV, Andreeva IV. Pathogenesis and diagnosis of postoperative macular edema. Vestnik oftal’mologii. 2017;134(41):107-112. (In Russ.) https://doi.org/10.17116/oftalma20181341107-112
  15. Anchala AR, Pasquale LR. Neovascular glaucoma: a historical perspective on modulating angiogenesis. Semin Ophthalmol. 2009;24(2):106-112. https://doi.org/10.1080/08820530902800959
  16. Chalam KV, Brar VS, Murthy RK. Human ciliary epithelium as a source of synthesis and secretion of vascular endothelial growth factor in neovascular glaucoma. JAMA Ophthalmol. 2014;132(11):1350-1354. https://doi.org/10.1001/jamaophthalmol.2014.2356
  17. Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina. 2007;27(7):816-824. https://doi.org/10.1097/IAE.0b013e318042d32c
  18. Kim M, Lee C, Payne R, Yue BY, Chang JH, Ying H. Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review. Surv Ophthalmol. 2015;60(6):524-535. https://doi.org/10.1016/j.survophthal.2015.04.003
  19. Simha A, Braganza A, Abraham L, et al. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2013;10:CD007920. https://doi.org/10.1002/14651858.CD007920
  20. Mosaed S, Minckler DS. Aqueous shunts in the treatment of glaucoma. Expert Rev Med Devices. 2010;7(5):661-666. https://doi.org/10.1586/erd.10.32
  21. Kovacic Z, Ivanisevic M, Rogosic V. Cyclocryocoagulation in treatment of neovascular glaucoma. Lijec Vjesn. 2004;126(9-10):240-242.
  22. Fong AW, Lee GA, O’Rourke P. Management of neovascular glaucoma with transscleral cyclophotocoagulation with diode laser alone versus combination transscleral cyclophotocoagulation with diode laser and intravitreal bevacizumab. Clin Experiment Ophthalmol. 2011;39(4):318-323. https://doi.org/10.1111/j.1442-9071.2010.02449.x
  23. Delgado MF, Dickens CJ, Iwach AG. Long-term results of noncontact neodymium:yttrium-aluminum-garnet cyclophotocoagulation in neovascular glaucoma. Ophthalmology. 2003;110(5):895-899. https://doi.org/10.1016/S0161-6420(03)00103-9
  24. Kiuchi Y, Nakae K, Saito Y. Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol. 2006;244:1627-1632. https://doi.org/10.1007/s00417-006-0321-7
  25. Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther. 2008;25(5):438-443. https://doi.org/10.1007/s12325-008-0047-5
  26. Saito Y, Higashide T, Takeda H. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. Acta Ophthalmol. 2010;88(1):96-102. https://doi.org/10.1111/j.1755-3768.2009.01648.x
  27. Waisbourd M, Shemesh G, Kurtz S, et al. Topical bevacizumab for neovascular glaucoma: a pilot study. Pharmacology. 2014;93(3-4):108-112. https://doi.org/10.1159/000358600
  28. Duch S, Buchacra O, Milla E, Andreu D, Tellez J. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients. J Glaucoma. 2009;18(2):140-143. https://doi.org/10.1097/IJG.0b013e318170a747
  29. Grisanti S, Biester S, Peters S, et al. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol. 2006;142(1):158-160. https://doi.org/10.1016/j.ajo.2006.02.045
  30. Grover S, Gupta S, Sharma R, Brar VS, Chalam KV. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol. 2009;93(2):273-274. https://doi.org/10.1136/bjo.2008.145714
  31. Yazdani S, Hendi K, Pakravan M, Mahdavi M, YaseriM. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma. 2009;18(8):632-637. https://doi.org/10.1097/IJG.0b013e3181997211
  32. Sugimoto Y, Mochizuki H, Okumichi H, et al. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2010;248(11):1601-1609. https://doi.org/10.1007/s00417-010-1406-x
  33. Saito Y, Higashide T, Takeda H, Murotani E, Ohkubo S, Sugiyama K. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab. Am J Ophthalmol. 2010;149(6):964-972.e1. https://doi.org/10.1016/j.ajo.2010.01.008
  34. Kotecha A, Spratt A, Ogunbowale L, dell’Omo R, Kulkarni A, Bunce C, Franks WA. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series. Arch Ophthalmol. 2011;129(2):145-150. https://doi.org/10.1001/archophthalmol.2010.350
  35. Waisbourd M, Shemesh G, Kurtz S. Topical bevacizumab for neovascular glaucoma: a pilot study. Pharmacology. 2014;93:108-112. https://doi.org/10.1159/000358600
  36. Luke J, Nassar K, Luke M, Grisanti S. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma — results from a prospective interventional case series. Graefes Arch Clin Exp Ophthalmol. 2013;251(10):2403-2413. https://doi.org/10.1007/s00417-013-2428-y
  37. Tang M, Fu Y, Wang Y. Efficacy of intravitreal ranibizumab combined with Ahmed glaucoma valve implantation for the treatment of neovascular glaucoma. BMC Ophthalmol. 2016;16:7. https://doi.org/10.1186/s12886-016-0183-7
  38. Liu L, Xu Y, Huang Z, Wang X. Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma: assessment of efficacy and complications. BMC Ophthalmol. 2016;16:65. https://doi.org/10.1186/s12886-016-0183-7
  39. Soo Hoo JR, Seibold LK, Pantcheva MB, Kahook MY. Aflibercept for the treatment of neovascular glaucoma. Clin Experiment Ophthalmol. 2015;43(9):803-807. https://doi.org/10.1111/ceo.12559
  40. Al-Mahmood S, Colin S, Farhat N, Thorin E, Steverlynck C. Potent in vivo antiangiogenic effects of GS-101 (5’-TATCCGGAGGGCTCGCCATGCTGCT-3’), an antisense oligonucleotide preventing the expression of insulin receptor substrate-1. J Pharmacol Exp Ther. 2009;329(2):496-504. https://doi.org/10.1124/jpet.108.147496
  41. Cloutier F, Lawrence M, Goody R, Lamoureux S, Al-Mahmood S. Antiangiogenic activity of aganirsen in nonhuman primate and rodentmodels of retinal neovascular disease after topical administration. Invest Ophthalmol Vis Sci. 2012;53(3):1195-1203. https://doi.org/10.1167/iovs.11-9064
  42. Lorenz K, Scheller Y, Bell K. A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma — the STRONG study: study protocol for a randomised controlled trial. Trials. 2017;18(1):128. https://doi.org/10.1186/s13063-017-1861-3
  43. Andrés-Guerrero V, Perucho-González L, García-Feijoo J, et al. Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma. Adv Ther. 2016;34(2):378-395. https://doi.org/10.1007/s12325-016-0461-z
  44. Dong Z, Gong J, Liao R, Xu S. Effectiveness of multiple therapeutic strategies in neovascular glaucoma patients: A PRISMA-compliant network meta-analysis. Medicine (Baltimore). 2018;97(14):e9897. https://doi.org/10.1097/MD.0000000000009897
  45. Rodrigues GB, Abe RY, Zangalli C, Sodre SL, Donini FA, Costa DC, Leite A, Felix JP, Torigoe M, Diniz-Filho A, de Almeida HG. Neovascular glaucoma: a review. Int J Retina Vitreous. 2016;2:26. https://doi.org/10.1186/s40942-016-0051-x
  46. Wakabayashi T, Oshima Y, Sakaguchi H. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008;115(9):1571-1580, 80.e1-3. https://doi.org/10.1016/j.ophtha.2008.02.026
  47. Surguch VK, Erichev VP. Antiangiogenic therapy for neovascular glaucoma. Glaukoma. 2010;2:55-58. (In Russ.)
  48. Surguch VK, Erichev VP. Change in the newly formed vessels of the anterior segment of the eye after antiangiogenic therapy (angiographic study). Glaukoma. 2013;3(1):46-50. (In Russ.)
  49. Sachdeva MM, Moshiri A, Leder HA, Scott AW. Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms. J Ophthalmic Inflamm Infect. 2016;6(1):2. https://doi.org/10.1186/s12348-015-0069-5
  50. Xu Y, Tan CS. Safety and complications of intravitreal injections performed in an Asian population in Singapore. Int Ophthalmol. 2017;37(2):325-332. https://doi.org/10.1007/s10792-016-0241-4
  51. Slabaugh M, Salim S. Use of anti-VEGF agents in glaucoma surgery. J Ophthalmol. 2017;2017:1645269. https://doi.org/10.1155/2017/1645269
  52. Wen JC, Reina-Torres E, Sherwood JM. Intravitreal anti-VEGF injections reduce aqueous outflow facility in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;58(3):1893-1898. https://doi.org/10.1167/iovs.16-20786
  53. Van Bergen T, Vandewalle E, Van de Veire S, Dewerchin M, Stassen JM, Moons L. The role of different VEGF isoforms in scar formation after glaucoma filtration surgery. Exp Eye Res. 2011;93(5):689-699. https://doi.org/10.1016/j.exer.2011.08.016
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.